Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-03-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company's board regarding the use of idle funds for cash management, including details on investment types, amounts, risk controls, and approvals. It is a formal disclosure of a financial decision made by the board, not a financial report or earnings release. The document length is short (2190 characters) and it does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive content about the decision itself. The content fits best with a Capital/Financing Update (CAP) as it relates to the company's use of funds and investment activities.
2025-03-27 Chinese
国邦医药2024年度独立董事述职报告（张晟杰）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to the "2024 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, and activities during the year 2024. The content includes descriptions of board meetings, committee participation, oversight of financial and operational matters, communication with shareholders, and evaluation of company governance and compliance. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or certification. It is a management-related report focusing on the independent director's role and activities, which fits best under the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-03-27 Chinese
国邦医药2024年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度董事会审计委员会履职情况报告" which translates to the "2024 Annual Board Audit Committee Performance Report." It details the audit committee's activities, including supervision of external auditors, internal audit guidance, evaluation of internal controls, and review of financial reports. The document is a report on the audit committee's duties and oversight rather than the full annual financial report or audit report itself. It is not a short announcement but a substantive report on audit committee activities. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related oversight information, excluding full annual reports. The document does not contain full financial statements but focuses on audit committee performance and audit oversight, consistent with AR classification. The document length is 3040 characters, which is substantive but not a full annual report. Therefore, the best classification is AR with high confidence.
2025-03-27 Chinese
国邦医药2024年度独立董事述职报告（任明川）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, oversight, and opinions on company governance and financial matters during the year 2024. The content includes descriptions of the director's activities, attendance at meetings, oversight of financial reporting and internal controls, and opinions on related party transactions, financial audits, and remuneration. It is not a full annual report (10-K), nor an audit report (AR), but rather a management or governance-related report focusing on the independent director's role and activities. It is not a brief announcement or a certification letter, but a substantive report. This fits best under Board/Management Information (MANG) as it relates to board-level reporting and management oversight. The document length (5241 characters) supports it being a full report rather than a short announcement. Therefore, the classification is MANG with high confidence.
2025-03-27 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' or 'Media/Public Sentiment Management Policy' of Guobang Pharmaceutical Group Co., Ltd. It outlines internal policies and procedures for managing media and public sentiment, including organizational structure, responsibilities, principles, and confidentiality obligations. There is no financial data, no mention of financial results, no regulatory filings or announcements of voting results, no capital or financing updates, no earnings information, no legal proceedings, no merger or acquisition activity, and no other typical financial or corporate event disclosures. The document is a governance-related internal policy document rather than a report or announcement. It is not a report publication announcement because it is substantive and not merely announcing a report. It is not a certification or attestation. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is 3572 characters long, which is substantive enough to be a full policy document rather than a brief announcement.
2025-03-27 Chinese
立信会计师事务所关于国邦医药2024年度非经营性资金占用及其他关联资金往来情况的专项审计报告
Regulatory Filings
2025-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.